Emerging and Re-Emerging Diseases Conference 2017 logo

Understand the opportunities for your business in reacting to global threats like malaria, dengue and Ebola

ABOUT THE
EMERGING AND RE-EMERGING DISEASES CONFERENCE

 

The Ebola outbreak of 2014 brought emerging and re-emerging diseases screaming into the limelight.

This brought with it a renewed vigor for vaccines from the public and a catalyst for the scientific community to progress vaccines for diseases such as Ebola, Malaria, Dengue, and Chikungunya. Use this Conference to meet with and demonstrate your knowledge to the organizations who are pushing forward in this area.

SCROLL DOWN FOR THE 2017 AGENDA

 

2017 AGENDA

Emerging Diseases, Tuesday 11 April 2017

Dr Peter Hotez
Emerging Diseases
09:10

How new drivers of infectious diseases are changing the way we handle NTDs

  • Geographic significance: How NTDs are no longer limited to poverty driven areas only
  • Bringing together  the G20 countries to tackle this globally
Dr Walla Dempsey
Emerging Diseases
09:40

How have we handled the Zika outbreak and what prevention measures have we taken as Zika continues to spread in the US?

  • How long until we are likely to be able to vaccinate vulnerable people that are most at risk?
  • Have we responded quickly enough?
  • What about the Zika virus we now understand and what prevention measure have been implemented to mitigate risks
Dr Scott M White
Emerging Diseases
10:10

Developing vaccines for emerging diseases: Addressing Zika, MERS and Ebola

  • Role of validated platforms in rapidly addressing emerging infectious diseases – safety and speed of development
  • Generating high level of immune responses in animal models and demonstrating challenge efficacy
  • Results from the first in human studies on safety and immunogenicity
10:40

Networking coffee break

Dr Wolfgang Bender
Emerging Diseases
11:40

Addressing vaccine development against emerging mosquito-transmitted diseases

  • Building on key competencies from a successful bench to market development of a Japanese Encephalitis vaccine
  • Valneva’s vaccine candidates against Zika, Chikungunya and Yellow fever
Dr Giuseppe Ciaramella
Emerging Diseases
11:55

The development of an mRNA vaccine against Zika virus

Dr James Jackson
Emerging Diseases
12:10

Working with government and industry partners to tackle biodefence diseases and our efforts in developing a vaccine against Zika

Dr Cheryl Keech
Emerging Diseases
12:40

Design and implementation of clinical trials in an emerging epidemic: Flavivirus Case Study

  • Clinical development challenges associated with the design and conduct of emerging epidemic trials
  • Current status of Zika Vaccine candidates in Clinical Development
  • Geographical Considerations: Epidemiology v Trial Locations
  • Considerations for Zika Vaccine Clinical Development Strategy
13:10

Networking Lunch & Poster Session

Dr Steven Reed
Emerging Diseases
14:40

The value of adjuvants and vaccines to be used to prevent disease and in post-exposure

  • Using host-directed therapeutics to prevent anti-microbial resistance
  • Mechanisms of the delivery in assisting the immune system to fight reoccurrence
  • Blurring the lines between the therapeutic and preventative nature of vaccines
  • Broadening the immune response using adjuvants for faster and longer-lasting effects
  • Rapid response techniques to contain outbreaks
Thomas Lingelbach
Emerging Diseases
15:10

Development of a novel vaccine for protection against Lyme borreliosis: PhI trial of Valneva’s Lyme vaccine candidate VLA15

  • Supporting evidence from pre-clinical data of protection from Borrelia species pathogenic for humans
  • Product development and public health strategy
Dr Jeffrey Ulmer
Emerging Diseases
15:40

Technologies to facilitate a rapid vaccine response to newly emerging pathogens

  • With the increasing number of emerging diseases, what technologies and platforms are available to help identify and prevent outbreaks?
  • New vaccines are all moving away from traditional vaccine approaches so how do we choose one platform over another?
  • Being prepared: Promising new platform technologies applicable for vaccine development against emerging pathogens
16:10

Networking coffee break

Dr Francisco Diaz-Mitoma
Emerging Diseases
16:40

Sci-B-Vac™: Hepatitis B vaccine Phase III program update

Helene Boigard
Emerging Diseases
16:55

Zika Virus-Like Particle (VLP) Based Vaccine

Dr Julie Waterbury
Emerging Diseases
17:10

An update on the safety, immunogenicity, and efficacy of the rVSVΔG-ZEBOV-GP Ebola Vaccine

  • Further results from three separate clinical trials to  distribute its vaccine by the end of 2017
  • Interim results demonstrated the vaccine’s ability to cut the risk of infection in people
  • Regulatory experience and lessons learned that could help with progressing the Zika outbreak
Dr Barney Graham
Emerging Diseases
17:40

Spike Trimers: A General Vaccine Solution for Beta-coronaviruses

  • Vaccine candidates in development: The current landscape
  • Targeting the MERS-CoV S protein
  • Immunogens based on full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates
Dr Thomas Richie
Emerging Diseases
18:10

Vaccine progression and developments against Malaria

  • The first malaria vaccine providing durable protection against infection with malaria parasites
  • PfSPZ vaccine has shown to provide protection against infection with malaria parasites for at least 14 months
  • Next steps to make the vaccine a reality to benefit the huge population still at risk
18:40

Chair’s closing remarks and close of congress day 2

18:45

Networking Drinks & Party

last published: 09/Apr/17 15:46

 

Emerging Diseases, Wednesday 12 April 2017

Dr Laura Martin
Emerging Diseases
09:10

Shigella vaccine built on GMMA technology – Using outer membrane particles shed from genetically engineered bacteria for cost effective vaccines

  • The potential impact and cost-effectiveness of a Shigella vaccine in developing countries
  • Potential of the GMMA technology in vaccine strategies targeting poverty related diseases
Dr Lisa Danzig
Emerging Diseases
09:40

Interactive discussion: Using the recent license of Cholera vaccine as a case study

  • Single-dose live oral cholera vaccine shown to protect cholera in protection in a human cholera challenge model
  • Lessons learned from the regulatory approval that may be applicable to other vaccines
  • Next steps to have this available for children and for use outside of the US
John Fraser
Emerging Diseases
10:25

Tools to assess and advance Group A Streptococcus Vaccines

 
  • Assembly and genome sequencing of a representative strain panel 
  • Economic analysis of vaccine implementation in Australia and New Zealand, compared to other public health initiatives
  • Development of a reference assay
  • A clinical development plan to move forward with
10:40

Networking coffee break

Dr Akshay Goel
Emerging Diseases
11:30

Paratyphoid A fever & vaccine development: The importance of vaccines with the rise of antibiotic resistance

 
  • Role of vaccines as a part of an integrated program to combat the spread of antibiotic resistance 
  • The need for a more effective Typhoid vaccine and an adequate supply needed to meet demand, particularly in the most affected countries
  • Overview of the promising candidates in the pipeline
Dr Akshay Goel, Senior Vice President - R&D, Biological E. Limited
Richard Walker
Emerging Diseases
12:00

Strategies for developing vaccines against ETEC

The need for an ETEC vaccine and the current landscape of candidates  will be reviewed.  This will be followed by an in depth analysis of the most advanced of these candidates, ETVAX, an inactivated whole cell vaccine which PATH is developing in collaboration with Scandinavian BioPharma. This product exceeded its primary endpoints in a phase 1 trial in Finnish volunteers and is currently being evaluated in a descending age study in Bangladesh.  It is being administered with and without the mucosal adjuvant dmLT.  It may in the future be combined with a vaccine candidate for Shigella.
12:30

Networking Lunch & Poster Session

Dr Alan R. Hinman
13:40

The eradication of Polio: Have we succeeded?


-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
Prof Robert Daum
14:10

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria


-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
Panel discussion
14:40

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?


-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
15:30

Chair’s closing remarks and close of congress

last published: 09/Apr/17 15:46

 

Sign up for event updates

 

WHO ATTENDS?

  • Pharma
  • Biotech
  • National and International Government
  • Non-Profit Organizations
  • Academics And Research Institutions ​

JOB TITLES

  • CEO / CSO / COO
  • CMO / Head of Scientific Affairs
  • Head of Infectious / Emerging / Neglected Disease
  • Head of R&D
  • Head of Virology
  • Head of Immunology​ ​

 

 

WHO SPONSORS?

This is a great opportunity for specialists in emerging diseases from:

  • Platform Technology Providers
  • Logistics / Cold Chain
  • Biotechs
  • Big Pharma